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Abstract
Background: Tenosynovial giant cell tumor (TGCT) is a rare, benign lesion affecting the synovial lining of joints, bursae, and
tendon sheaths. It is generally characterized as a locally aggressive and often recurring tumor. A distinction is made between
localized- and diffuse-type. The impact of TGCT on daily living is currently ill-described.
Objective: The aim of this crowdsourcing study was to evaluate the impact of TGCT on physical function, daily activities,
societal participation (work, sports, and hobbies), and overall quality of life from a patient perspective. The secondary aim was
to define risk factors for deteriorated outcome in TGCT.
Methods: Members of the largest known TGCT Facebook community, PVNS is Pants!!, were invited to an e-survey, partially
consisting of validated questionnaires, for 6 months. To confirm disease presence and TGCT-type, patients were requested to
share histological or radiological proof of TGCT. Unpaired t tests and chi-square tests were used to compare groups with and
without proof and to define risk factors for deteriorated outcome.
Results: Three hundred thirty-seven questionnaires, originating from 30 countries, were completed. Median age at diagnosis
was 33 (interquartile range [IQR]=25-42) years, majority was female (79.8% [269/337]), diffuse TGCT (70.3% [237/337]), and
affected lower extremities (knee 70.9% [239/337] and hip 9.5% [32/337]). In 299 lower-extremity TGCT patients (32.4% [97/299])
with disease confirmation, recurrence rate was 36% and 69.5% in localized and diffuse type, respectively. For both types, pain
and swelling decreased after treatment; in contrast, stiffness and range of motion worsened. Patients were limited in their
employment (localized 13% [8/61]; diffuse 11.0% [21/191]) and sport-activities (localized 58% [40/69]; diffuse 63.9% [147/230]).
Compared with general US population, all patients showed lower Patient-Reported Outcomes Measurements Information
System-Physical Function (PROMIS-PF), Short Form-12 (SF-12), and EuroQoL 5 Dimensions 5 Levels (EQ5D-5L) scores,
considered clinically relevant, according to estimated minimal important difference (MID). Diffuse versus localized type scored
almost 0.5 standard deviation lower for PROMIS-PF (P<.001) and demonstrated a utility score of 5% lower for EQ-5D-5L
(P=.03). In localized TGCT, recurrent disease and ≥2 surgeries negatively influenced scores of Visual Analog Scale
(VAS)-pain/stiffness, SF-12, and EQ-5D-5L (P<.05). In diffuse type, recurrence resulted in lower score for VAS, PROMIS-PF,
SF-12, and EQ-5D-5L (P<.05). In both types, patients with treatment ≤1year had significantly lower SF-12.
Conclusions: TGCT has a major impact on daily living in a relatively young and working population. Patients with diffuse
type, recurrent disease, and ≥2 surgeries represent lowest functional and quality of life outcomes. Physicians should be aware
that TGCT patients frequently continue to experience declined health-related quality of life and physical function and often remain
limited in daily life, even after treatment(s).
(Interact J Med Res 2018;7(1):e4)   doi:10.2196/ijmr.9325
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Introduction
Tenosynovial giant cell tumor (TGCT), previously pigmented
villonodular synovitis (PVNS), is a rare, proliferative neoplasm
affecting the synovial lining of joints, bursae, and tendons
sheaths. According to growth pattern, a radiological distinction
is made between a well-circumscribed lesion (localized type)
and a locally more aggressive lesion (diffuse type) [1,2]. The
incidence rate reveals its rarity: for localized type (excluding
digits), 10.2 per million person-years and for diffuse type, 4.1
per million person-years. TGCT is a monoarticular disease,
concerning large joints, typically about the knee: 46% in
localized-type and 64% to 75% in diffuse-type. Male-female
ratio is about 1:1.5 for both types, with a median age at the time
of TGCT diagnosis of 30 to 50 years [1-3]. Most common initial
symptoms are pain, stiffness, and swelling. Additional symptoms
might be limited range of motion, instability, giving way, and
locking complaints [4]. Due to these unspecific signs and the
rarity of the disease, patients frequently experience a delay of
years in diagnosis [3,5,6]. To treat these symptoms, current
treatment of choice is surgical excision, either by arthroscopic
or open synovectomy [7]. After surgical resection, high
recurrence rates are known, with the localized type up to 50%
and the diffuse type up to 92% [6].
Once TGCT is diagnosed, a high health care burden is identified
with a significant increase in health care costs, ambulatory
expenses, and physical therapy [8]. In describing treatment
benefits and standard oncologic end points, patient-reported
outcome instruments are increasingly used. Visual Analog Scale
(VAS) for worst pain-stiffness and Patient-Reported Outcomes
Measurement Information System-Physical Function
(PROMIS-PF) questionnaires were identified as most valuable
measures for TGCT symptoms in a relatively small TGCT
patient cohort (n=22) [4].
The impact of TGCT symptoms following surgery(s) and
recurrences on daily living, sports, and work activities is
currently ill-described. Although TGCT is not considered lethal,
this tumor is hypothesized to have major impact on daily living.
Especially diffuse disease is notorious for its negative influence
on both local recurrence risk and functional outcome [9].
Use of an e-survey is a unique possibility to reach a large elusive
TGCT population and to globally evaluate impact of TGCT on
patients’ daily life. This crowdsourcing study evaluates effect
of TGCT on physical function, daily activities, societal
participation (work, sports, and hobbies), and overall quality of
life from a patient perspective. Secondary aim is to define risk
factors for deteriorated outcome in TGCT.
Methods
Study Design
This cross-sectional crowdsourcing study was performed at
Leiden University Medical Center, Leiden, The Netherlands,
in accordance with good clinical practice [the Declaration of
Helsinki (2000)]. This study was conducted from December
2016 until end of May 2017 (6 months), using the largest known
online TGCT community on Facebook, PVNS is Pants!!, to
gather participants for the Web-based questionnaire. The study
was conducted conforming to the Checklist for Reporting
Results of Internet E-Surveys (CHERRIES), the checklist
focusing on Web-based surveys [10] (Multimedia Appendix 1).
NetQuestionnaire (NetQ) was used to complete the TGCT
questionnaire. NetQ is a professional Web-survey software,
approved for (bio)medical research and supported by the Leiden
University Medical Center (LUMC). Respondents were able to
review and change their answers before submitting. 
Patients and Recruitment
Members of PVNS is Pants!! were requested to participate in
our international crowdsourcing study “Evaluation of
Tenosynovial Giant Cell Tumor on daily living” (Multimedia
Appendix 2). At the time of writing (December, 2016), this
closed Facebook community contained 2179 members. A
patient-friendly TGCT-research-related message was posted in
the Facebook community every 4 weeks to encourage TGCT
patients to complete the questionnaire. Additional study updates
and easily understandable information on TGCT were posted
on the page of a newly designed TGCT study Facebook account
[11].
All members of the Facebook community had access to the
questionnaire. Solely patients with TGCT diagnosis were
requested to participate in this study. To achieve a higher level
of evidence, confirmation of TGCT (histological or radiological)
was requested after completing the questionnaire. Sending
(anonymized) medical reports to our protected email account
was highly desirable but left to the discretion of the participant.
Members of Facebook community PVNS is Pants!! have been
notified that (research-minded) doctors are members of this
closed Facebook community for several years. Participation in
this study was voluntary, and no incentives were offered.
Informed consent was given by completing the survey. This
study was approved by the Institutional Review Board (CME)
from our institution (registration number P16.232, December
5, 2016).
Unique site visitors were determined by Internet protocol (IP)
addresses. When duplicate entries were detected, the most recent
one was included in the analyses. All password-protected
documents were only accessible to TGCT researchers and saved
on the secured departmental drive of our hospital. Data of
participants were anonymized when medical proof was received
or when the participant did not respond to our third request for
medical confirmation. To ascertain TGCT diagnosis and TGCT
type, all medical reports were verified by 2 TGCT researchers
(MJLM, RP). When in disagreement, medical reports were
checked by the senior orthopedic surgeon (MAJS) for final
conclusion.
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Questionnaire
On the very active Facebook community PVNS is Pants!!,
several patient-initiated questionnaires and polls were
performed, for instance, about treatments, coping strategies,
daily limitations, and emotional struggles. Members expressed
their desire for studies regarding these topics, since the majority
of TGCT studies concern physical function and recurrent disease
as outcome parameters. Therefore, a Web-based questionnaire,
using mostly validated questionnaires, was composed to describe
impact of TGCT on health-related outcome and daily living
from a patient perspective. A prerequisite was that the
questionnaire would be relevant for the heterogeneous TGCT
population: for different large joints, different ages, males or
females, localized or diffuse type, and for patients at different
treatment stages.
To assess relevance and completeness of our questionnaire, a
pilot test with the composed questionnaire was performed. One
dedicated orthopedic oncologic surgeon (MAJS), 2 medical
doctors (MJLM, RP), and 5 TGCT patients in our outpatient
clinic, all fluent in written and spoken English language, tested
the e-survey. Validated questionnaires were used as published
by the owners. After the pilot test, a few nonvalidated questions
were added or rephrased (Multimedia Appendix 3).
Nonvalidated questions concerned patient and tumor
characteristics, medical history, TGCT symptoms, performed
treatments, recurrences, employment status, sports, and number
of visits to general practitioner and orthopedic surgeon. The
majority of questions had a multiple-choice character, including
a not applicable or other answer option. The exact number of
nonvalidated questions depended on given answers. For instance,
patients with an extensive TGCT-related history were asked
additional questions on their history, in contrast to the patients
awaiting their initial treatment.
Validated questionnaires on physical function and quality of
life included: VAS for worst pain and stiffness in the last 24
hours, PROMIS-PF items, Short Form-12 Health Survey
(SF-12), and EuroQoL EQ-5D-5L (EQ-5D-5L Descriptive
System and EQ-5D-5L VAS). A total of 32 validated questions
were included. VAS for pain and stiffness was used to estimate
patient’s pain and stiffness intensity for the past 24 hours: no
pain/stiffness at all (0) and worst pain/stiffness imaginable (10).
PROMIS-PF instruments were used to measure self-reported
capability of physical activities. In this study, short forms of
physical functioning for lower and upper extremity were used
with 5 response options: without any difficulty (5), with a little
difficulty (4), with some difficulty (3), with much difficulty (2),
and unable to do (1). Raw score was calculated by summing up
the values of the response to each question and was converted
into a T score by the Assessment Center from PROMIS-PF. A
mean of a standardized T score of 50 with a standard deviation
of 10 reflects the general US population [12].
The SF-12, a generic measure of health status, functioned as a
shorter alternative for the SF-36. Number of answer options
differed per question. Physical component summary (PCS) score
and mental component summary (MCS) score were calculated.
Similar to PROMIS-PF, the general US population had a mean
of 50 with a standard deviation of 10 [13].
The EQ-5D-5L is one of the most commonly used generic health
status measures in the world. Its descriptive system comprises
5 dimensions of health: mobility, self-care, usual activities, pain
or discomfort, and anxiety or depression, with the following 5
levels of problems per dimension: no problems (1), slight
problems (2), moderate problems (3), severe problems (4), and
extreme problems (5) [14]. For each participant, answers per
dimension were combined into an EQ-5D-5L health state. This
health state was converted into a single index value (so-called
utility score) for quality of life, by using the Crosswalk Index
Value Calculator version 1.0 from the EuroQoL Group [15].
Utility scores were measured on an ordinal scale of 0 to 1, with
0 indicating death and 1 indicating full health [16]. Crosswalk
valuation set for US population was used for all participants,
since majority of the patients originated from the United States
(42.7% [144/377]). A specific analysis, called sensitivity
analysis, was performed using the valuation set for UK
population, the second largest patient population (20.2%
[68/337]) in this study. Scores calculated with US valuation set
were compared with scores obtained by using UK valuation set
to assess representativeness of the scores from validated
questionnaires [14] (Multimedia Appendix 4).
Statistical Analysis
NetQ automatically captured questionnaire answers into an
SPSS 23 file. Evaluation of TGCT on daily living was mainly
descriptive.
Chi-square tests were used to compare patient groups with and
without medical proof regarding gender (male vs female), TGCT
localization (knee vs other large lower extremity joints [hip,
ankle, and foot]), initial surgery (arthroscopy vs [one- or
two-staged] open synovectomy), recurrence (yes vs no), total
number of surgeries (1 surgery vs ≥2 surgeries), and time since
last treatment for TGCT (≤1 year ago vs >1 year ago)
(Multimedia Appendix 5).
Independent t tests were used to compare the mean age at the
time of diagnosis and continuous scores of validated
questionnaires. All reported P values were two-tailed. Statistical
significance level was defined at P<.05.
Effect size, as a quantitative measure of the strength of a
phenomenon, was calculated for both PROMIS-PF and SF-12
scores in localized- and diffuse-type patients, compared with
general US population score. Effect size, or Cohen d, is the ratio
of difference between two means divided by the standard
deviation, expressed in standard deviation units. An effect size
between 0.2 and 0.5 is considered small, 0.5 and 0.8 medium,
and above 0.8 large [17].
The minimal important difference (MID), a quality of life
measure, represents the smallest difference or change beyond
statistical significance in an outcome measure score that would
be considered clinically relevant by the value patients place on
change. MID for EQ-5D-5L Index Scores is estimated between
.037 and .069, based on the simulation-based instrument-defined
MID estimates [18]. MID for PROMIS-PF was determined by
Yost et al in advanced-stage cancer patients [19]. Differences
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in T scores between 4.0 and 6.0 were considered clinical
relevant. MID for SF-12 PCS and MCS scores were calculated
by Díaz-Arribas et al in >450 patients with low back pain and
were stated at >3.29 for PCS and >3.77 for MCS [20].
Results
The TGCT questionnaire was initiated by 445 participants within
a time frame of 6 months. For the present analysis, only fully
completed, unique questionnaires (337) were included (Figure
1). The majority of incomplete questionnaires were early
dropouts with a great lack of information and therefore
unsuitable for analysis.
Most patients were female (79.8% [269/337]) and median age
at diagnosis was 33 (interquartile range [IQR]=25-42) years.
Patients originated from 30 different countries (United States:
42.7% [144/337]; United Kingdom: 20.2% [68/337]; and the
Netherlands: 12.8% [43/337]). TGCT was typically located in
lower extremities: knee (70.9% [239/337]), hip (9.5% [32/337]),
ankle (11.0% [37/337]), and foot (3.0% [10/337]). Diffuse
TGCT was diagnosed in 237 of 337 (70.3%) patients (Table 1).
According to few TGCT patients with TGCT located in the
upper extremity, 12 out of 337 patients (3.6%) were excluded
for further analyses. Additionally, 26 out of 337 lower-extremity
patients (7.7%) with unknown TGCT type were also excluded
(Figure 1). Questionnaires of 299 lower-extremity patients with
localized or diffuse TGCT were analyzed.
Disease Confirmation
Confirmation of TGCT was sent by 32.4% (97/299) of
lower-extremity participants. In 81% (78/97) TGCT type was
in concordance with questionnaire answer, in 16/97 (16%)
medical reports TGCT type did not match the answer and was
therefore adjusted according to the report and 3/97 (3%) patients
answered TGCT type unknown and TGCT type was added in
consistence with the report.
No important differences between patients with and without
medical proof were detected (Multimedia Appendix 5), neither
for localized or diffuse type separately. Therefore, patients with
medical proof were considered representative for the entire
study population and additional analyses were performed for
the entire patient group.
Medical History and Tenosynovial Giant Cell Tumor
Symptoms
5/69 (7%) and 29/230 (12.6%) in localized- and diffuse-type
patients, respectively, had an autoimmune disease, mostly
diabetes mellitus type I, Hashimoto, psoriasis, and thyroid
disease. In all, 22/69 (32%) of localized-type and 70/230
(30.4%) of diffuse-type patients experienced a trauma at
TGCT-affected joint, before diagnosis; sports injuries or fall
incidents leading to a sprain or rupture. In all, 5/69 (7%) and
12/230 (5.2%) of patients in localized and diffuse TGCT had
surgery of the affected joint before TGCT diagnosis,
respectively, for example, meniscus or anterior cruciate ligament
(ACL) reconstructions. In all, 6/230 (2.6%) of diffuse-type
participants experienced both trauma and surgery before TGCT
diagnosis.
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Figure 1. Flowchart Tenosynovial Giant Cell Tumor (TGCT) questionnaire. Q: Questionnaires; L: Localized-TGCT; D: Diffuse-TGCT; U: Unknown-type
TGCT.
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Table 1. Patient and tumor characteristics (n=337).
ValueCharacteristic
41 (32-50)Age at time of questionnaire (years), median (IQRa)
33 (25-42)Age at time of TGCT diagnosis (years), median (IQR)
337 (100)Total, N (%)
Gender, n (%)
68 (20.2)Male
269 (79.8)Female
Country of residence, n (%)
144 (42.7)United States of America
68 (20.2)United Kingdom
43 (12.8)The Netherlands
22 (6.5)Australia
14 (4.2)Canada
46 (13.6)Other
TGCTb localization, n (%)
239 (70.9)Knee
32 (9.5)Hip
37 (11.0)Ankle
10 (3.0)Foot
4 (1.2)Shoulder
6 (1.8)Elbow
2 (0.6)Wrist
7 (2.1)Otherc
TGCT type, n (%)
72 (21.4)Localized
237 (70.3)Diffuse
28 (8.3)Unknown
aIQR: interquartile range (25-75%).
bTGCT: tenosynovial giant cell tumor.
cOther included multiple TGCT locations (all in lower extremity).
Table 2. Initial and current symptoms for localized and diffuse tenosynovial giant cell tumor (TGCT) (n=337).
Diffuse TGCT (n=230)Localized TGCT (n=69)TGCTa-related symptom
Current, n (%)Initial, n (%)Current, n (%)Initial, n (%)
170 (73.9)186 (80.9)47 (68)57 (83)Pain
139 (60.4)190 (82.6)29 (42)53 (77)Swelling
148 (64.3)128 (55.7)41 (59)38 (55)Stiffness
149 (64.8)140 (60.9)29 (42)38 (55)Limited range of motion
aTGCT: tenosynovial giant cell tumor.
Majority of patients (92.6% [277/299]) were treated for TGCT.
For both types, pain and swelling improved compared with
initial situation. After treatment, more patients reported stiffness
and limited range of motion (Table 2). A minority of the patients
(<6%) currently experienced additional symptoms, including
instability, buckling, hyperextension and/or hypermobility,
clicking or locking or popping of joint, numbness, electric
shocks, tingling, dull ache, heat of the affected joint, or
hematoma.
Interact J Med Res 2018 | vol. 7 | iss. 1 | e4 | p.6http://www.i-jmr.org/2018/1/e4/
(page number not for citation purposes)
Mastboom et alINTERACTIVE JOURNAL OF MEDICAL RESEARCH
XSL•FO
RenderX
Treatment(s)
Most performed initial surgery was arthroscopic synovectomy
(57% [38/67] localized, 53.8% [113/210] diffuse) and open
synovectomy, one- or two-staged (39% [26/67] localized, 42.9%
[90/210] diffuse). In all, 5/67 (7%) localized-type and 53/210
(25.2%) diffuse-type patients had adjuvant therapies after initial
surgery, mainly radiotherapy and 90-Yttrium. In all, 24/67 (36%)
of localized type had recurrent disease after 1.5 (range 1-6)
years, in contrast to 146/210 (69.5%) of diffuse type after 2.2
(range 1-23) years (Table 3). Additional surgery was performed
in 23/67 (34%) of localized type and 125/210 (59.5%) of diffuse
type, predominantly open synovectomy (one- or two-staged).
Impact of Tenosynovial Giant Cell Tumor on Daily
Life
Due to TGCT, 8/61 (13%) and 21/191 (11.0%) of working
population in localized and diffuse TGCT, respectively, was
currently not able to (fully) perform their employment. Of these
patients, 4/8 (50%) localized patients and 17/21 (81%) diffuse
patients had recurrent disease. Majority of patients, 40/69 (58%)
of localized and 147/230 (63.9%) of diffuse type, were unable
to perform sport activities. In these patients, recurrent disease
presented in 15/40 (38%) of localized type and 94/147 (63.9%)
of diffuse type. Disease burden was estimated by mean number
of visits to general practitioner (5.6 [range 1-50] visits for
localized type, 7.1 [range 1-60] visits for diffuse type), and
orthopedic surgeon (8.3 [range 1-97] visits for localized type,
11.9 [range 1-100] visits for diffuse type).
Results of validated questionnaires are shown in Table 4
(localized vs diffuse type), Table 5 (localized type), and Table
6 (diffuse type). Results with positive association are described
in the text.
Worst Pain and Stiffness in Last 24 Hours: Visual
Analog Scale Score
For localized type, best VAS pain score was 2.76 and VAS
stiffness score was 2.80. In diffuse type, best scores for pain
and stiffness were 3.04 and 3.08, respectively. Patients with
recurrence of TGCT had deteriorated VAS score for pain and
stiffness (P=.01 localized type and P<.001 diffuse type). In
localized type, patients with ≥2 surgeries had higher VAS score
for pain (P=.02) and stiffness (P=.01).
Patient-Reported Outcomes Measurements
Information System-Physical Function: T Score
All TGCT patients had clinically relevant impaired T scores
(44.5 and 41.3 for localized and diffuse type, respectively)
compared with the general US population (T score of 50).
Corresponding effect size was medium for localized type
(d=0.55) and large for diffuse type (d=0.87). When comparing
both types, diffuse-type patients scored lower (P<.001). In
localized type, female patients scored lower (P=.04).
Diffuse-type recurrent patients had decreased scores (P=.02).
Table 3. Treatment characteristics of 277 treated tenosynovial giant cell tumor (TGCT) patients.
Diffuse TGCT (n=210)Localized-TGCTa (n=67)Treatment
Initial surgery, n (%)
113 (53.8)38 (57)Arthroscopic synovectomy
90 (42.9)26 (39)Open synovectomy (one- or two-staged)
0 (0.0)3 (4)Combined arthroscopic/open synovectomy
5 (2.4)0 (0)Total joint replacement/(tumor) prosthesis
2 (1.0)0 (0)Amputation
53 (25.2)5 (7)Adjuvant therapy, n (%)
18 (8.6)4 (6)Radiotherapy
14 (6.7)1 (1)90-Yttrium
15 (7.1)0 (0)Systemic
6 (2.9)0 (0)Otherb
146 (69.5)24 (36)Recurrent disease, n (%)
125 (59.5)23 (34)Additional surgery, n (%)
32 (15.2)7 (10)Arthroscopic synovectomy
74 (35.2)10 (15)Open synovectomy (one- or two-staged)
4 (1.9)1 (1)Combined arthroscopic/open synovectomy
12 (5.7)2 (3)Total joint replacement/(tumor) prosthesis
3 (1.4)3 (4)Amputation
aTGCT: tenosynovial giant cell tumor.
bOther adjuvant therapies were cryosurgery, burning tools, steroid injections, or combination of multiple adjuvant therapies.
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Table 4. Risk factor comparison of 69 localized versus 230 diffuse tenosynovial giant cell tumor (TGCT) of lower extremities.
EQ-5D-5L DSh
utility score, 0
death and 1 full
health, MID
.037–.069
SF-12, MCSg score,
mean 50 (SD 10), MID
>3.77
SF-12e, PCSf score,
mean 50 (SD 10), MID
>3.29
PROMIS-PFc T score,
mean 50 (SD 10), MIDd
4.0–6.0
Worst stiffness
VAS score, 0
best score and 10
worst score
Worst pain VASb
score, 0 best
score and 10
worst score
TGCTa
-type
P valueMeanP valuedMeanP valuedMeanP valued iMeanP valueMeanP valueMean
.030.76.400.2547.5.080.9540.5<.0010.5544.5.143.46.243.36Localized
0.720.3846.31.1938.10.8741.34.013.79Diffuse
aTGCT: tenosynovial giant cell tumor.
bVAS: Visual Analog Scale.
cPROMIS-PF: Patient-Reported Outcomes Measurement Information System-Physical Function.
dMID: minimal important difference represents the smallest difference or change beyond statistical significance in an outcome measure score that would
be considered important by the value patients place on change ref [18-20].
eSF: Short-Form.
fPCS: physical component summary.
gMCS: mental component summary.
hDS: descriptive system.
id: Cohen d or effect size, ratio of difference between 2 means divided by the standard deviation.
Short Form-12 Health Survey: Physical and Mental
Component Summary Score
In comparison with general US population (score of 50), both
types had impaired PCS (40.5 localized and 38.1 diffuse type)
and MSC scores (47.5 localized and 46.3 diffuse type). In all
patients in all compared groups, PCS score was clinically
relevant declined, in contrast to MCS score which did not
transcend the MID threshold in majority of patient groups. A
large effect size was calculated for mean PCS scores (0.95 and
1.19 for localized and diffuse type, respectively) and a medium
effect size (0.25 and 0.38 for localized and diffuse type,
respectively) for MCS scores. In localized type, higher number
of surgeries (≥2) affected PCS score negatively (P=.03).
Localized- and diffuse-type patients who underwent treatment
for TGCT ≤1 year ago, showed lower PCS score (P=.04
localized, P=.01 diffuse). In diffuse type, female patients
demonstrated a decreased MCS score (P=.04), as well as patients
with recurrence of TGCT (P=.04).
EuroQoL 5 Dimensions 5 Levels Health Questionnaire:
Index Value
All patients, in all groups (Tables 4-6), presented declined
EQ5D-5L utility scores compared with full health (1), and all
scores transcended MID threshold. Overall, utility score was
lower in diffuse patients compared with localized patients
(P=.03). In localized type, participants with recurrence of TGCT
and ≥2 surgeries scored lower (P=.01 and P=.02, respectively).
Similarly, diffuse patients with recurrence had decreased scores
(P=.02). Median health question VAS score was 75 (IQR 65-85)
for localized and 75 (IQR 56.5-85) for diffuse type. No
differences between scores calculated with US and UK valuation
sets were detected in sensitivity analysis (Multimedia Appendix
4).
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Table 5. Risk factor comparison of 69 localized tenosynovial giant cell tumor (TGCT) of lower extremities.
EQ-5D-5L DSg
utility score, 0
death and 1 full
health, MID
.037-.069
SF-12, MCSf
score, mean 50
(SD 10), MID
>3.77
SF-12d, PCSe
score, mean 50
(SD 10), MID
>3.29
PROMIS-PFb T
score, mean 50
(SD 10), MIDc
4.0-6.0
Worst stiffness
VAS score, 0
best score and 10
worst score
Worst pain VASa
score, 0 best
score and 10
worst score
Risk-factors
P valueScoreP valueScoreP valueScoreP valueScoreP valueScoreP valueScore
Gender
.18.81.4249.4.2343.3.0448.5.793.290.532.93Male (n=14)
.7547.039.843.53.513.47Female (n=55)
Age of diagnosis
.95.76.0745.4.7440.1.6344.1.823.39.9973.36<35 years (n=36)
.7749.840.945.03.553.36≥35 years (n=33)
TGCT localization
.41.77.6347.2.4341.0.5744.2.073.13.083.04Knee (n=53)
.7448.638.845.54.564.44Hip, ankle, foot, other
(n=16)
Initial surgery
.92.76.7347.2.9640.7.5244.2.633.26.583.45Arthroscopy (n=38)
.7748.040.845.63.623.04Open surgeryh (n=26)
Recurrence
.01.70.2745.7.1738.3.2042.8.014.71.014.50Yes (n=24)
.8048.541.745.42.802.76No (n=45)
Total no. of surgeries
.02.79.1948.4.0342.2.2045.4.012.86.022.771 surgery (n=44)
.7145.036.742.64.654.48≥2 surgeries (n=23)
Last treatment for TGCT
.29.74.3446.0.0437.6.0642.4.383.81.263.77≤1 year ago (n=31)
.7848.342.646.13.193.00>1 year ago (n=36)
aVAS: Visual Analog Scale.
bPROMIS-PF: Patient-Reported Outcomes Measurement Information System-Physical Function.
cMID: minimal important difference represents the smallest difference or change beyond statistical significance in an outcome measure score that would
be considered important by the value patients place on change ref [18-20].
dSF: Short-Form.
ePCS: physical component summary.
fMCS: mental component summary.
gDS: descriptive system.
hOne- or two staged open synovectomy.
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Table 6. Risk factor comparison of 230 diffuse tenosynovial giant cell tumor (TGCT) of lower extremities.
EQ-5D-5L DSg
utility score, 0
death and 1 full
health, MID
.037-.069
SF-12, MCSf
score, mean 50
(SD 10), MID
>3.77
SF-12d, PCSe
score, mean 50
(SD 10), MID
>3.29
PROMIS-PFb T
score, mean 50
(SD 10), MIDc
4.0-6.0
Worst stiffness
VAS score, 0
best score and 10
worst score
Worst pain VASa
score, 0 best
score and 10
worst score
Risk factors
P valueScoreP valueScoreP valueScoreP valueScoreP valueScoreP valueScore
Gender
.17.75.0449.0.1139.9.2342.2.714.13.703.63Male (n=51)
.7145.637.541.03.983.84Female (n=179)
Age of diagnosis
.22.73.3846.9.0739.2.0742.1.093.74.583.70<35 years (n=119)
.7145.636.840.44.323.89≥35 years (n=109)
TGCT localization
.40.73.9846.3.9938.1.2941.6.073.92.933.78Knee (n=170)
.7146.338.140.54.553.82Hip, ankle, foot, other
(n=60)
Initial surgery
.25.73.6445.6.8638.3.6641.6.644.19.823.93Arthroscopy (n=113)
.7046.438.041.24.013.84Open surgeryh (n=190)
Recurrence
.02.70.0445.1.4937.7.0240.5<.0014.55<.0014.23Yes (n=146)
.7548.238.742.73.083.04No (n=84)
Total no. of surgeries
.44.73.8946.1.4838.7.2042.0.093.74.693.791 surgery (n=86)
.7146.337.740.84.383.94≥2 surgeries (n=124)
Last treatment for TGCT
.17.70.5945.6.0135.4.1740.4.374.35.374.10≤1 year (n=72)
.7346.539.541.84.003.76>1 year ago (n=138)
aVAS: Visual Analog Scale.
bPROMIS-PF: Patient-Reported Outcomes Measurement Information System-Physical Function.
cMID: minimal important difference represents the smallest difference or change beyond statistical significance in an outcome measure score that would
be considered important by the value patients place on change ref [18-20].
dSF: Short-Form.
ePCS: physical component summary.
fMCS: mental component summary.
gDS: descriptive system.
hOne- or two staged open synovectomy.
Discussion
Principal Findings
The name of the largest online community of patients with
TGCT, PVNS is pants!!, suggests impact on quality of life. One
of the community members motivated the name: “Pants is
British slang for crap or garbage.” To date, it is unknown what
the effect of TGCT on daily living is. A questionnaire was
composed in consultation with TGCT patients to determine
functional, socioeconomic, and health burden for TGCT patients.
We intended to evaluate TGCT in the real world and concluded
that TGCTs have a large impact on daily living, with declined
health-related quality of life and limitations in daily activities,
sports, work, and hobbies: especially the diffuse type of lower
extremities and recurrent disease including multiple surgeries.
Limitations
The most important limitation to this study is selection bias. By
using crowdsourcing to gather data, it is likely to have a higher
number of patients with severe or recurrent diseases [21].
Consequently, when extrapolating these results to generally
described populations of TGCT patients in literature, care should
be taken not to overestimate the decreased physical function
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and additional socioeconomic limitations. TGCT usually affects
young adults. Since younger patients are more likely to be on
the World Wide Web, and our included patient population had
a median age of 33 (25-42) years at time of diagnosis, also in
concordance with the WHO classification [1,2] and Mastboom
et al [3], we considered our participants representative for the
heterogeneous disease TGCT. Additionally, the CHERRIES
was completed. This checklist provides an understanding of the
sample (self-)selection and its possible differences from a
representative sample [10] (Multimedia Appendix 1). An
additional limitation to this study is that patients in different
stages of different treatments were included. To assess
comparability within study population, we compared patients
who had treatment less than a year ago with performed treatment
over a year ago. No positive associations were discovered,
except for the SF-12 PCS score in both types. This underlines
the postoperative limitations during the first year of follow-up
after treatment. As we set out to evaluate impact of TGCT on
daily living in the real world heterogeneous TGCT population,
the inclusion of patients in different treatment stages matched
intention of our study. Furthermore, a known disadvantage of
quality of life questionnaires (eg, SF-12) is the generalizability
of the questions. Impaired overall quality of life could be
attributed to TGCT but also to additional physical abnormalities
or psychological problems. Also questionnaires may be
completed by patients that have been ill-informed on their
disease. In all, 28 patients filled out unknown type of TGCT,
and 16% of patients who confirmed TGCT with medical proof
filled out localized TGCT instead of diffuse TGCT or vice versa.
Undeniably, differentiating in localized and diffuse TGCT is
challenging even for (un)specialized physicians. The relatively
high recurrence rate in this study could also be reflected by
unawareness of disease specifics. Recurrence rates in our study
were 36% and 70% for localized and diffuse type, compared
with on average 4% to 6% (up to a maximum of 50%) and 14%
to 40% (up to a maximum of 92%) according to van der Heijden
et al [6], respectively. It is conceivable that residual disease or
clinical symptoms were filled out as recurrent disease.
The use of self-reported questionnaires harbors the risk of
incorrectly answered questions. One could argue that all patients
should have been analyzed together, not subdividing into
localized and diffuse type. However, differences between two
types are major, and therefore separate analyses were necessary
for a realistic view of impact of TGCT on daily living.
Crowdsourcing
The presumed definition of crowdsourcing is the practice of
obtaining services, ideas, or content by collecting contributions
from a comprehensive group from an online community rather
than from traditional data suppliers [9]. However, the exact
definition for crowdsourcing remains controversial, as 40
definitions originating from 32 unique articles, published
between 2006 and 2011, were described by Estellés-Arolas [22].
It is therefore challenging to well define crowdsourcing
coherently. After analyses of the 40 (sometimes contrasting)
definitions, 8 characteristics common to any given
crowdsourcing initiative were found: the crowd, the task at hand,
the recompense obtained, the crowdsourcer or initiator of the
crowdsourcing activity, what is obtained by them following the
crowdsourcing process, the type of process, the call to
participate, and the medium. First, in our study, the crowd is
presented by patients with TGCT (preferably confirmed by
medical reports). Second, the task at hand is completing a
questionnaire about the effect of TGCT on daily living. Third,
participating in this study was voluntary, therefore no
recompenses were offered. Fourth, the initiators of this study
are members of the Facebook group PVNS is Pants!!
accompanied with the executors, known as the authors of this
paper. Fifth, the researchers and subsequently the participants
and TGCT patients gain more knowledge on the impact of
TGCT on daily living. Sixth, the type of process is an evaluation
process, aiming to evaluate effect of TGCT on daily living.
Seventh, all patients with TGCT, fluent in English language,
were invited to complete the questionnaire. Lastly, the medium
Facebook was used to broadcast the questionnaire.
Facebook is the best applicable social network site for survey
research, because it is continuously growing, internationally
known and exceeds 2 billion users globally (June 2017). The
Facebook community PVNS is Pants!!, created in 2009, is the
largest TGCT online support group and mainly consists citizens
of the United States. On this very active, closed Facebook
community, patients are daily updating experiences on their
disease, ask for advice from fellow TGCT patients, and comment
on other posts to provide their knowledge or sympathy. By
actively posting and commenting on research proposals, patients
expressed their willingness to participate in research on TGCT.
From these posts, we learned that adequate patient information
on TGCT is lacking. Our crowdsourcing study stimulated
patients’ involvement in research and was an opportunity to
align research questions with the public’s interest [23,24]. TGCT
is a rare disease and time to definitive diagnosis is prolonged
due to unspecific symptoms and unfamiliarity of the disease
[5]. A challenge in studying a rare disease is the lack of big
data. Crowdsourcing is an effective and low-cost alternative to
traditional methods of participant recruitment due to the
possibility to reach large groups of individuals in a relatively
short time frame [25]. Van der Heijden et al [9] concluded that
crowdsourcing is a promising way for evaluation of rare
diseases. Czajka et al [21] used crowdsourcing to efficiently
recruit a global cohort and is the largest study on patients with
multiple hereditary exostoses. Crosier et al [26] used Facebook
to recruit patients with auditory hallucinations; within 6 weeks,
over 250 patients had completed this survey. Pohlig et al [27]
concluded that enrollment of patients in prospective studies is
time-consuming and could be facilitated by use of
crowdsourcing.
To obtain a higher level of scientific value, patients were
requested for medical proof to ascertain TGCT diagnosis. To
our knowledge, no other crowdsourcing studies considered
disease confirmation. Patient data and outcome for validated
questionnaires were comparable for patients with and without
medical proof. Patients were not uniformly diagnosed and
treated as they originated from 30 different countries globally.
Neither was distinguished between treatment in peripheral or
tertiary referral centers. Nevertheless, we consider our study
group a reflection of the current worldwide situation and believe
that declined impact on daily living is clinically relevant for all
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patients. In contrast to malignant diseases, survival rates are not
of interest for TGCT with its benign character. According to
high recurrence rates, quality of life (prior and after treatment)
is essential to evaluate.
Patient-Reported Outcome Measures
Patient reported outcome measures (PROMs) are increasingly
used in health policy, patient-centered care, and shared clinical
decision making [28]. In the era of personalized medicine,
patient involvement is increasing in shared decision making for
different treatment strategies with functional outcome and
quality of life. In our study, members of the largest online TGCT
community were involved in establishing the questionnaire
Evaluation of TGCT on daily living.
Functional outcome and health-related quality of life are only
spars reported for TGCT. Four studies have reported on
standardized PROMS [4,9,29,30]. Currently, validated PROMS
for TGCT patients do not exist. In accordance with Gelhorn et
al [4], VAS for worst pain and stiffness and PROMIS-PF
questionnaires were used. Conform van der Heijden et al [9,29]
and Verspoor et al [30], the SF-12, a quality of life
questionnaire, was included, known as the shorter version of
the SF-36. One study identified a high health care burden with
a significant increase in health care costs, ambulatory costs, and
physical therapy in 9328 TGCT patients [8].
In benign diseases, including TGCT, death is not an outcome
variable. Besides tumor reduction, critical endpoint measures
are clinical relevance and impact of treatment. Currently, clinical
TGCT studies lack specific and validated PROMs to document
treatment-induced symptomatic, functional, and economic (back
to work) improvement [31]. To obtain an impression of physical
function and quality of life in TGCT patients, participants in
our study were requested to complete different validated
questionnaires. In our experience, PROMIS-PF was most useful
in determining these functional factors. To minimize the
multitude of questions and include the most important
components for clinical TGCT studies, we would propose a
combination of PROMIS-PF and a short quality of life
questionnaire, for instance EQ5D5L, in clinical practice.
Risk Factors for Deteriorated Outcome
Risk factors for deteriorated outcome in our study were
diffuse-type TGCT, recurrent disease, and ≥2 surgeries
performed. This is in concordance with current literature on risk
factors for a high recurrence rate. According to the necessity of
mutilating surgeries to treat recurrences, we considered risk
factors for recurrent disease comparable to risk factors for
deteriorated outcome.
Higher recurrence rate in diffuse TGCT compared with localized
TGCT is exuberant described [2,5-7,30,32-34]. Bruns et al [34]
described 173 patients treated in 10 orthopedic departments in
Germany and Austria and reported higher recurrence rates in
institutions treating less than 20 cases for TGCT, in diffuse
disease, in the hip joint and after arthroscopy. Schwartz et al
[35] described 99 patients with TGCT in the knee, hip, elbow,
or shoulder. They concluded that localization in the knee,
previous surgical procedures, and incomplete synovectomy
were related significantly to higher number of subsequent
recurrences. On the basis of current literature and to investigate
possible risk factors for recurrent disease thoroughly, gender,
age at time of diagnosis, TGCT localization, initial surgery,
presence of recurrence, total number of surgeries, and time since
last treatment for TGCT, were compared.
Conclusions
TGCTs have major impact on daily living in a relatively young,
working population (median age at diagnosis, 33 years).
Majority of symptoms improve after treatment, however,
symptoms remain in about half of the TGCT patients; especially
in patients with diffuse type, recurrent disease, and ≥2 surgeries.
The high recurrence rate in diffuse TGCT results in clinically
important deteriorated outcome in physical function and
health-related quality of life. In preventing recurrent disease,
and its deteriorated outcome, an extensive mutilating surgery
might be necessary. Physicians should be aware that TGCT
patients frequently experience symptoms and limitations in daily
life and societal participation (work, sports, and hobbies), even
after treatment(s). We deem it important for future research to
evaluate treatment, including its effectiveness on improving
quality of daily living. With this study, we hope to increase
knowledge on TGCT among treating physicians, highlight the
importance of quality of life, and to offer research-based
information to patients.
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